Ascentage Pharma Group International (AAPG) Non-Current Deffered Revenue (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $29.6 million as the latest value for Q4 2025.
- For Q4 2025, Non-Current Deffered Revenue rose 674.21% year-over-year to $29.6 million; the TTM value through Dec 2025 reached $29.6 million, up 674.21%, while the annual FY2025 figure was $929000.0, 75.34% down from the prior year.
- Non-Current Deffered Revenue hit $29.6 million in Q4 2025 for Ascentage Pharma Group International, up from $3.8 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $34.9 million in Q4 2023 and bottomed at $3.8 million in Q4 2024.
- Average Non-Current Deffered Revenue over 3 years is $22.8 million, with a median of $29.6 million recorded in 2025.
- Year-over-year, Non-Current Deffered Revenue plummeted 89.03% in 2024 and then surged 674.21% in 2025.
- Ascentage Pharma Group International's Non-Current Deffered Revenue stood at $34.9 million in 2023, then plummeted by 89.03% to $3.8 million in 2024, then soared by 674.21% to $29.6 million in 2025.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $29.6 million, $3.8 million, and $34.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.